Kornimate/medical-research-clean huggingface dataset:
utilizing wearable device to observe the clinical response of copd patients treated with combined bronchodilator and home-based pulmonary rehabilitation program

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the effectiveness of combined bronchodilator and exercise training on improving exercise capacity has been reported in copd. however, little is known about effect of respective treatment in a real-time monitoring. investigators applied wearable devices in monitoring continuously in copd patients under treatment of combined dual bronchodilator and exercise training and research on associated inflammatory biomarkers profiles change

the prevalence of chronic obstructive pulmonary disease (copd) has increased year by year and the estimated mortality rate by 2030 will be in the fourth place. estimated global prevalence of copd in the population over age 40 is about 9-10% of the population. in taiwan, the prevalence is about 16%. copd is characteristic of irreversible airflow obstruction due to the pathological changes in the small airways, lung parenchyma and pulmonary vessels with chronic inflammation of the specific immune cells, as well as structural changes. although studies have suggested that exercise training in patients with copd benefit the physical activity, but the anti-inflammatory benefits is unknown.consider individual needs, this study will use the home mobile coach from dr. liu domestic development program to further investigate chronic obstructive pulmonary disease patients after receiving this training program,performance and analysis in the clinical laboratory to explore anti-inflammatory and pro-inflammatory between relevance and mechanisms in patients with copd under real-time wearable devices monitoring

Eligibility criteria:
inclusion criteria: 1. global initiative for chronic obstructive lung disease (gold) according to diagnostic criteria of chronic obstructive pulmonary disease (age ≧ 40 years old and ≦ 85 years old), that the use of post-bronchodilator inhalation, pulmonary function test results of the forced expiratory volume first second (fev1.0) / forced vital capacity (fvc) \<70% 2. copd patients is not currently accepting any pulmonary rehabilitation program 3. currently in a stable condition, after researchers explained the purpose of this study, the researchers agreed to participate. exclusion criteria: 1. asthma, bronchiectasis, tuberculosis, pneumoconiosis, or other pulmonary diseases 2. associated with neuromuscular function disorders such as hemiplegia or no independent walking function; 3. severe heart disease, such as acute myocardial infarction, serious or heart failure, etc. 4. diagnosed with severe mental disorders such as dementia or poor compliance 5. acute exacerbation or infection in 3 months
a "less-rapid" sequence anesthetic induction/intubation sequence? does apneic oxygenation by means of an oxygenating laryngoscope blade prolong the "duration of apnea without desaturation" in paralyzed non-obese and morbidly obese patients?

Conditions: Apneic Oxygenation

Summary: the study will test the efficacy of the pentax awstm video laryngoscope (vls) equipped with a p blade (figure 1) as the means to provide apneic oxygenation (ao) and prolong duration of apnea without desaturation (dawd) in non-obese and morbidly obese females.

pre-oxygenation/de-nitrogenation for three minutes of spontaneous breathing or alternatively four to eight deep breaths prior to rapid sequence anesthetic induction/intubation (rsii) in patients with healthy lungs, low oxygen demands and normal hemoglobin levels allows up to eight minutes of safe apnea time or dawd. the study will test the efficacy of the pentax awstm video laryngoscope (vls) equipped with a p blade as the means to provide apneic oxygenation and prolong dawd. the p blade sports a suction conduit which can equally well provide a conduit for oxygen administration. the initial phase of the study will include non-obese healthy (asar 1-2) women patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery. subsequently a cohort of morbidly obese patients (bm i ≥ 40 kg/m2) also requiring gynecologic abdominal access will be recruited for investigation. participants of each group (obese, non-obese) will be randomized to apneic oxygenation with the the pentax aws laryngoscope or no apneic oxygenation.

Eligibility criteria:
inclusion criteria: 1. female patients, 2. american society of anesthesiologists rating 1-2, 3. aged 18 through 65 years of age 4. elective gynecological surgery via an abdominal approach (laparoscopic or open) 5. already consented to general anesthesia necessitating endotracheal intubation. 6. are candidates for anesthesia using laryngeal mask airway if needed exclusion criteria: 1. patient refusal to enter study 2. history of difficult mask ventilation 3. history of, or anticipated difficult intubation 4. heavy smokers (\> 10 cigarettes per day) 5. asthma 6. chronic obstructive pulmonary disease 7. heart disease 8. renal or liver disease 9. neurological disease. 10. women scored at ≥ 3/4 on the modified mallampati scale 30. 11. women exhibiting other signs of a potential difficult intubation (limited neck flexion or extension; neck circumference \> 30 cm; prominent incisors) 12. patients with a baseline resting oxygenation level of less than 95%.
ultralow dose thoracic computed tomography in immunocompromised patients

Conditions: Leukemia

Summary: patients with bone marrow cancer are more susceptible to chest infections than healthy adults; marrow ablation treatment further compromises their immune status and increases the risk of fungal opportunistic infection, which is associated with a high fatality rate. therefore, it is critical to achieve early and accurate diagnosis of fungal infection when these patients become febrile. at the mount sinai hospital (msh) and the university health network (uhn), the standard of care (soc) to exclude a chest infection in immunocompromised (ic) patients is chest computed tomography (ct) using low dose ct (ldctt).

as patients may have several febrile episodes during their hospital stay, the cumulative dose from ldctt scans can be significant and increase the lifetime risk of inducing a second cancer. the aim of this project is to determine whether a 75% reduction in radiation dose for ldctt in other words, an ultralow dose chest ct (uldctt) at a dose comparable to chest x-ray, maintains the diagnostic image quality for detection of fungal chest infection in ic patients. if successful, uldctt will be adopted as soc imaging at princess margaret cancer center (pm) for these patients.

Eligibility criteria:
inclusion criteria: 1. all immunocompromised patients clinically referred for ldctt to the medical imaging department at pm 2. 18 years and older exclusion criteria: 1. patients that cannot follow study procedures

Keywords: bone marrow transplant infection computed tomography radiation dose
effectiveness of cognitive behavior therapy for persons with depression

Conditions: Depression

Summary: this was a randomized controlled clinical trial (rct) carried out in three different hospitals in dhaka city, bangladesh.

this was a randomized controlled trial, conducted to determine the effectiveness of cbt for depression delivered by trained therapists with an adapted bengali cbt (bacbt) manual, as compared to a control group. the main objective of the current study was to examine the efficacy of cbt for persons with major depression in bangladesh.

Eligibility criteria:
inclusion criteria: * diagnosed with major depression * must be able to take therapeutic session exclusion criteria: * active suicidal ideation * a co-morbid serious health condition * with psychotic features * currently on medication for depression * with an intellectual disability
a study of ddi in children with aids who have not had success with zidovudine

Conditions: HIV Infections

Summary: the purpose of this study is to make didanosine (ddi) available to children with aids who are clinically deteriorating on zidovudine (azt) or intolerant to azt and cannot enter the phase ii ddi programs due to protocol exclusion or geographic location.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * concomitant medications for the treatment of complications of aids. * caution: * concomitant use of ddi with the following drugs must be done with extreme caution: * other nucleosides (e.g., ganciclovir). * drugs with toxicities similar to those observed with ddi (e.g., phenytoin). * drugs with significant pancreatic toxicities, including many drugs used for treatment of major opportunistic infections. * use of sulfonamides or intravenous pentamidine for treatment of acute pneumocystis carinii pneumonia (pcp) requires discontinuation of ddi for a week following treatment of pcp. * caution should also be exercised with patients having intractable diarrhea or patients following a low sodium diet. patients must have the following: - diagnosis of aids. demonstrated either significant deterioration despite parenteral dosing with zidovudine (azt) or significant intolerance to azt. signed informed consent by parent or legal guardian. evaluations every 7-14 days while taking ddi for the first 4 months. monthly follow-up is required thereafter. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * acute pancreatitis or any history of pancreatitis. * seizures or a history of seizure disorder. * grade i or greater peripheral neuropathy. * preexisting cardiomyopathy. concurrent medication: excluded: * zidovudine (azt). * chemotherapy with cytotoxic agents. * avoid: * those agents that may cause pancreatitis such as: * pentamidine. * sulfonamides. * antituberculosis drugs. * cimetidine. * ranitidine. * corticosteroids. * note the cautionary statement in patient inclusion concurrent medication. patients with the following are excluded: * acute pancreatitis or any history of pancreatitis. * seizures or a history of seizure disorder. * grade i or greater peripheral neuropathy. * preexisting cardiomyopathy. prior medication: excluded within 15 days of study entry: * any anti-retroviral except zidovudine (azt). required: * zidovudine (azt).

Keywords: didanosine drugs, investigational acquired immunodeficiency syndrome zidovudine
immediate suboptimal result of mitral valve repair: late implications in a matched cohort study

Conditions: Mitral Regurgitation

Summary: mitral valve regurgitation is a pathology affecting the left atrioventricular valve, conditioning the loss of the normal unidirectionality of the atrioventricular flow and therefore volumetric and pressure overload of the left heart chambers. in industrialized countries, the most common etiology of mitral regurgitation is degenerative mitral disease. mitral valve repair surgery represents the gold standard for the treatment of severe degenerative mitral regurgitation. the expected optimal result would be the absence of residual post-procedural mitral regurgitation, even if it is not uncommon to obtain a valve with residual regurgitation of a mild degree. in some cases, for various reasons (technical difficulties, long aortic clamping time, advanced age, high pre-operative surgical risk), a suboptimal result is accepted, i.e. a post-procedural residual mitral regurgitation of even a moderate degree ( 0, 1+, or 2+/4+). the aim of the present study is to evaluate the late clinical and echocardiographic implications of suboptimal mitral valve repair with a paired-data cohort study


Eligibility criteria:
inclusion criteria: * study group: * presence of severe degenerative mitral regurgitation treated by mitral valve repair between 2006 and 2013; * presence of moderate residual mitral regurgitation at discharge. * control group: * presence of severe degenerative mitral regurgitation treated by mitral valve repair between 2006 and 2013; * presence of residual mitral regurgitation of at least mild grade at discharge. exclusion criteria: * none
effect of topically-applied milrinone or nitroglycerin on internal mammary artery free flow

Conditions: Internal Mammary Artery Syndrome; Vasodilation

Summary: forty-six consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled. after the left ima was harvested, free flow was measured under controlled hemodynamic conditions before any intervention (flow 1) and at a mean of 12.5 minutes after the topical application of one of three agents (milrinone, nitroglycerin or normal saline) on the ima (flow 2).

fifty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study. patients were randomly assigned to receive the topical application of one of three agents: milrinone (baxter pharmaceuticals, ahmedabad, india) 10 mg in 20 ml of dextrose 5%, nitroglycerin (caspian tamin pharmaceutical, guilan, iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control. all surgical procedures and measurements were carried out by a single surgeon who was blinded to the topical agent which was applied. each patient enrolled in the study gave a written informed consent, and the study protocol conforms to the ethical guidelines of the 1975 declaration of helsinki as reflected in a priori approval by the local human research committee. operative technique after sternal incision, the skeletonized left ima was harvested from the subclavian artery to its bifurcation with low-powered electrocautery, and major collaterals were ligated with hemoclips. following systemic heparinization (300 units/kg to achieve an activated clotting time target of 480 seconds), the ima was divided proximal to its bifurcation. the first ima flow (flow 1) was measured by reading the volume of blood ejected from the tip of the freely bleeding ima through a one-minute period. heart rate, mean arterial pressure and central venous pressure were documented at the same time. the tip of the artery was occluded with a bulldog clamp, and a swab which was soaked with the selected vasodilator at room temperature (18.0 to 20.0 degrees c) was wrapped around the ima, and was left undisturbed until the second set of measurements. cannulation for cardiopulmonary bypass was carried out, and the pump was used to transfuse or drain blood from the patient in order to restore the mean arterial and central venous pressures as nearly as possible to the previous values. systemic vasopressors or vasodilators were not used. the ima was then unwrapped and the second ima flow (flow 2) was measured in the same way. time, heart rate, and mean arterial and central venous pressures were also recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing elective primary coronary artery bypass grafting exclusion criteria: * patients who developed ischemic events during surgery

Keywords: milrinone graft coronary artery bypass grafting spasm
benign liver optimal core study (tissue acquisition comparison in benign liver disease)

Conditions: Liver Diseases

Summary: the primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of eus guided core liver biopsy for benign disease. the two techniques: "modified wet suction" and "slow pull" technique of collecting tissue from a liver biopsy via endoscopic ultrasound (eus).

each subject will have a biopsy performed via one of 2 different techniques: "modified wet suction", or "slow pull" technique. a randomization process will determine which technique. each subject shall undergo 2 passes (2 cores of tissue will be obtained - ideally from the right and left lobe of the liver. quality of tissue obtained via the 2 different techniques will be evaluated by number of fragments, length of specimens and number of tracts observed by the local pathologist and compared between the tissues obtained from the two techniques. .

Eligibility criteria:
inclusion criteria: * subjects that plan to undergo a liver biopsy via eus to confirm possible underlying liver disease or to determine stage, grade and presence of fibrosis for suspected benign etiology. * history of abnormal lfts * documented history of chronic liver disease * question of underlying liver disease as cause of abnormal imaging or symptoms which may be attributed to liver disorder * fatty liver disease * subjects 18 years of age or older * subject must be able to hold anticoagulants as per institutional standard of care * subjects must be deemed physically able to undergo anesthesia. this includes either monitored anesthesia care (mac) or general anesthesia. * subjects (or the subjects legally authorized representative \[lar\]) that have agreed to participate in the study and have signed informed consent * women of child bearing potential who are not pregnant as proven by a negative pregnancy test may be included. exclusion criteria * subjects that are unable to tolerate anesthesia for the procedure * subjects 17 or under * subjects whose anticoagulants cannot be held * subjects who cannot have or refuse eus guided procedure * subjects who are pregnant * inr \>1.5 * platelets 50,000 or less * subjects requiring control of bleeding on initial upper endoscopy * subjects requiring endoscopic mucosal resection * subjects with large volume ascites * subjects requiring pancreatic biopsies
25- hydroxyvitamin d levels in pregnancy and effects on pregnancy related disorders

Conditions: Vitamin d Deficiency; Preeclampsia; Preterm Delivery; Gestational Hypertension; Gestational Diabetes

Summary: evaluation of 25- hydroxyvitamin d levels in pregnant women in austria and potential related disorders hypothesis: austrian pregnant women are vitamin d deficient present vitamin d supplementation in pregnancy is insufficient vitamin d deficiency is associated with pregnancy related disorders like preeclampsia


Eligibility criteria:
inclusion criteria: * age\> 18 years * informed consent exclusion criteria: * chronic hypertension * kidney disease * lupus erythematodes * diabetes mellitus * malabsorption syndrome * hyperparathyroidism * surgery on the thyroid gland
magnetic resonance imaging (mri) of brain iron in neurodegenerative disease

Conditions: Neurodegenerative Diseases; Mild Cognitive Impairment

Summary: neurodegenerative diseases, such as alzheimer's disease, parkinson's disease, and multiple sclerosis are recognized as a major health concern at the present time. there is information in magnetic resonance imaging (mri) studies regarding the role of brain iron in normal brain aging that may be enhanced with the use of better scanning equipment and procedures, and by correlating this information with clinical data. this research study aims to develop and evaluate a number of techniques that can potentially improve the effectiveness of three tesla (3t) magnetic resonance imaging of neurodegenerative brain disorders.

eligibility: a healthy person without memory complaints or someone with neurodegenerative disease. however, the person should not have metal in the body (ie, pacemaker, implants, shrapnel, etc.), should not be pregnant, and should not have claustrophobic anxieties. study procedures: during a regular office visit, a neurologist will perform a routine physical and neurological examination, including your medical and family history, to determine your eligibility for this study. you will then be scheduled for a series of neuropsychological tests, which take between 1 to 1.5 hours, and an mri scan, which takes approximately 1 hour to complete. this is a longitudinal study and you may be asked to repeat these procedures approximately every six months for the duration of this 2 year project.

Eligibility criteria:
inclusion criteria: * 18 years or older * healthy person without memory complaints or person diagnosed with a neurodegenerative disease (ie, alzheimer's disease, parkinson's disease, multiple sclerosis) exclusion criteria: * mr contraindication such as metal in body (ie, pacemaker, implant, shrapnel, etc.) * pregnant * claustrophobic anxieties

Keywords: 3t mri neurodegenerative disease alzheimer's disease spectroscopy normal, healthy subject without memory complaint not pregnant mr compatible
comparison of two immunomodulatory formulas on the number of postoperative infections in head & neck cancer patients

Conditions: Head and Neck Neoplasms

Summary: the purpose of this study is to evaluate the effect of an immune formula , consumed 10 days before surgery , on the number and characteristics of postoperative infections for a period of 30 days in a group of oropharynx, hypopharynx , larynx and oral cavity squamous cell cancer patients, candidates for surgery.

68 subjects randomized into two study groups: 34 subjects consume the supplement of the study and 34 control consume the supplement impact. intervention period will be 10 days before surgery . the consume amount is 400 ml/ day. the subjects were stratified according to tumor location ( larynx and oral cavity and oropharynx, hypopharynx) and disease stage (early and advanced).

Eligibility criteria:
inclusion criteria: * men and women \>18 years * patients with histologically confirmed squamous cell cancer of the oropharynx, hypopharynx , larynx and oral cavity and candidates for neoplastic surgery (undergoing surgery) * adequate cultural level and understanding for the clinical trial. and agree to participate voluntarily in the study and give written informed consent * patients who do not participate in other clinical trials exclusion criteria: * patients with an active infectious process at the time of the study. * patients who have undergone radiotherapy / chemotherapy prior to surgery. * subjects diagnosed with type i diabetes mellitus * subjects who used oral hypoglycemic agents or insulin. * patients with severe kidney disease, heart, respiratory or liver. * patients with autoimmune diseases or immunosuppressive drugs used. * subjects with dementia, mental illness or diminished cognitive function. * subjects who refuse oral supplements. * subjects who consume vitamin supplements or artificial nutrition, and which can not be suspended at least 1 week before the study and do not accept to suspend it during the study. * subjects with morbid obesity (bmi ≥ 40 kg / m2). * pregnant or breastfeeding * patients diagnosed with epidermoid carcinoma t1 glottic, cordectomy candidate.
influenza vaccine attitudes, intent, and receipt: pediatric

Conditions: Vaccination; Influenza

Summary: influenza vaccine is recommended as routine care for all individuals who are at least 6 months of age and older. recently, questions about vaccine safety and concerns for side effects have increased, contributing to both influenza vaccine hesitancy and refusal. in an effort to educate parents and patients, public health entities and physicians give informational handouts in various forms. however, recent publications have found that pro-vaccine messages can have paradoxical effects on vaccine intentions, therefore further studies on vaccine related public health communication is needed. few, if any, studies have analyzed the relationship between influenza vaccine attitudes and intention with actual vaccine receipt in the pediatric population. these results will help to understand the relationship between parent's vaccine perception and the intent to vaccinate versus the child's receipt of the influenza vaccine, as well as to optimize educational information given to families regarding the influenza vaccine.


Eligibility criteria:
inclusion criteria: * age at least 6 months exclusion criteria: * receipt of influenza vaccination that season

Keywords: influenza vaccination